Hillevax inc
WebA Hillevax Inc Senior Scientist's compensation ranges from $130,751 to $157,117, with an average salary of $138,743. Salaries can vary widely depending on the region, the …
Hillevax inc
Did you know?
WebApr 6, 2024 · The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2024. HilleVax, Inc. was founded in 2024 and is headquartered in Boston, Massachusetts. WebJ.P. Morgan Sticks to Its Buy Rating for HilleVax, Inc (HLVX) 03/31/23-7:16AM EST TipRanks HilleVax GAAP EPS of -$0.56 03/20/23-5:31AM EST Seeking Alpha
WebMay 2, 2024 · HilleVax, Inc. (Nasdaq: HLVX), a biopharmaceutical company focused on the development and commercialization of novel vaccine candidates, reported today dosing of the first subjects in its previously announced Phase 2b clinical trial of HIL-214, the company’s virus-like particle (VLP) based vaccine candidate, for the prevention of … WebHilleVax, Inc. Document Metadata. Filed: March 17th, 2024. Contract Type Stock Restriction Agreement; Country United States; Jurisdiction California; Industry Biological products, (no disgnostic substances) Company HilleVax, Inc. SEC Filing ID 0000950170-23-008647; SEC Filing Type 10-k; SEC Exhibit ID ex-10;
WebWith over 60 years of experience, APLIX is one of the world’s leading hook and loop fastening system specialists. Our company aspires to provide our clients with innovative products and ... WebHilleVax Inc. annual balance sheet for HLVX company financials. Dow Jones, a News Corp company About WSJ. News Corp is a global, diversified media and information services company focused on ...
WebMar 13, 2024 · HilleVax Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
WebLife At Hillevax; Investors and Media. Overview; News & Events; Stock Information; Corporate Governance; Financial Information; IR Resources; Contact Us Rob Hershberg, M.D., Ph.D., is President, Chief Executive Officer and chairman of … Norovirus. Norovirus is the most common cause of viral acute gastroenteritis (AGE) … HilleVax has no obligation to provide any form of compensation in return for any … BOSTON, March 17, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: … Get in touch to find out more about HilleVax. 75 State St., Suite 100, Boston, … BOSTON, March 17, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: … Stock Information - Hillevax - Advancing a Vaccine to Protect Against Norovirus Corporate Governance - Hillevax - Advancing a Vaccine to Protect Against … Financial Information - Hillevax - Advancing a Vaccine to Protect Against Norovirus HilleVax priced its initial public offering on April 29, 2024. What is HilleVax’s fiscal … green hills pharmacyWebHilleVax, Inc. Common Stock (HLVX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. flwise.flwic.com/flwic/flwic.aspxWebHilleVax Inc. annual income statement. View HLVX financial statements in full, including balance sheets and ratios. flw insuranceWebMar 17, 2024 · BOSTON, March 17, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. HLVX, a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial ... fl winter rentals pet friendlyWeb330 feet: How tall the headquarters stands above Uptown Charlotte. 313,000 square feet: Size of the building. 24.1 seconds: How long it takes to reach the top floor from the lobby … green hills pharmacy njWebSep 8, 2024 · Norovirus vaccine . Less than two months after spinning out of Takeda Pharmaceuticals, HilleVax, Inc. secured $135 million in crossover financing to advance the development of its Phase III-ready norovirus vaccine.. The funds will be used to support further clinical development of its virus-like particle (VLP) based vaccine candidate, HIL … green hills pharmacy nashvilleWebApr 25, 2024 · HilleVax Inc. HLVX, -1.33% has set terms for its initial public offering, in which the Massachusetts-based biopharmaceutical company that focuses on developing novel … fl wise